What is Oncotype based on?

Your patient’s score is based on the expression of 21 specific genes from tumor tissue removed during the surgery or core biopsy.

How long does an Oncotype test take?

How long will it take to get the test results of the Oncotype DX test? Most test results are available within 7 to 10 days from the date your tumor sample is received by the Genomic Health laboratory. The Oncotype DX test report is sent to both your doctor and the pathologist who submitted the tissue sample.

Who qualifies oncotype?

If you have been diagnosed with DCIS (non-invasive) breast cancer (Stage 0) or early-stage invasive breast cancer (Stage I-IIIa), you may be eligible for the Oncotype DX test, a unique genomic breast cancer test that looks at the activity of certain genes in your tumor to provide personalized information not available …

How do you pronounce oncotype?

Pronunciation: (ON-koh-tipe …

What do you need to know about Oncotype DX?

Oncotype DX ® is a tumor profiling test. It helps determine the benefit of using chemotherapy in addition to hormone therapy to treat some estrogen receptor-positive (ER-positive) breast cancers.

How many patients have benefited from Oncotype IQ?

In collaboration with thousands of physicians around the world, over one million patients improved their outcomes with the Oncotype IQ portfolio of genomic tests. The only genomic test proven to predict a patient’s individual benefit from chemotherapy.

What does a high recurrence score on Oncotype mean?

A high recurrence score is 31 or over. If you have a high recurrence score, the chance that your cancer will return is higher. Adding chemotherapy to your cancer treatment increases the likelihood that the cancer will not come back. A high recurrence score doesn’t mean that your cancer will definitely come back.

How is the Oncotype map used in cancer treatment?

Rapid comprehensive genomic profiling to aid therapy selection in advanced cancer. The Oncotype MAP Pan-Cancer Tissue Test delivers rapid, comprehensive tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer. Real People. Real Results.